Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Tainted Synthetic Cannabis Leads to Coagulopathy Outbreak

By Arkady Rasin, MD; Jason Devgun, MD; and Theresa Kim, MD | on October 16, 2018 | 0 Comment
CME CME Now Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
Tainted Synthetic Cannabis Leads to Acquired Coagulopathy Outbreak

The elimination half-life of brodifacoum reportedly ranges from 16 to 36 days, with case reports of up to 270 days in intentional chronic exposures.6,7 Treatment with vitamin K1 provides active cofactor, bypassing the inhibited enzymes. However, considering the lack of regeneration of spent cofactor to vitamin K1, poor oral absorption of vitamin K1, and the long elimination half-life of many superwarfarins, patients must take regular large doses of vitamin K1 for a prolonged course to continue to produce clotting factors.

You Might Also Like
  • Intoxication from Synthetic-Cannabinoid-Receptor Agonists Often Missed
  • Case Report: Fear of COVID-19 Leads to Gangrene
  • Opinion: Emergency Physicians Need Better Education on Medical Cannabis
Explore This Issue
ACEP Now: Vol 37 – No 10 – October 2018

Diagnosis and Treatment

Suspect brodifacoum in patients presenting with unexplained bleeding, particularly hematuria and flank pain. Because brodifacoum is a superwarfarin, patients will present with a markedly elevated prothrombin time and INR. A history of synthetic cannabinoid or other illicit substance use may strongly support the diagnosis, especially in the setting of a cluster of cases. A thorough history addressing other causes of genetic or acquired coagulopathy is vital. Calling your local poison center may prove crucial in facilitating initial stabilization, long-term management, and coordination with the local health department.

Faced with a large-scale outbreak and the need to properly utilize available resources, we developed a treatment protocol that started with 10 mg of IV vitamin K1 and Kcentra, FFP, or factor eight inhibitor bypassing activity (FEIBA) for major bleeding. All patients who could tolerate oral delivery without active gastrointestinal bleeding were also started on oral vitamin K1 at 50 mg three times a day and then titrated every 48 hours to maintain an INR below 2.

Once patients were on a stable minimum dose, they were discharged. Every patient required reliable outpatient follow-up and access to vitamin K, which was complicated by the cost of vitamin K1, the large doses required, and the anticipated prolonged duration of treatment.


Complete the CME activity.


Dr. Rasin is a toxicology fellow at Toxikon Consortium in Chicago.

Dr. Devgun is a clinical instructor and attending at the University of Illinois at Chicago.

Dr. Kim is an attending physician at NorthShore University HealthSystem in Evanston, Illinois.

References

  1. King N, Tran MH. Long-acting anticoagulant rodenticide (superwarfarin) poisoning: a review of its historical development, epidemiology, and clinical management. Transfus Med Rev. 2015;29(4):250-258.
  2. Moritz E, Austin C, Wahl M, et al. Notes from the field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic cannabinoids – Illinois, March-April 2018. MMWR Morb Mortal Wkly Rep. 2018;67(21):607-608.
  3. Waien SA, Hayes D Jr, Leonardo JM. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N Engl J Med. 2001 30;345(9):700-701.
  4. Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol. 2007;82(7):656-660.
  5. Miller ME. Inside Alabama’s deadly spice craze. The Washington Post. April 24, 2015.
  6. Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood. 1990;76(12):2555-2559.
  7. Babcock J, Hartman K, Pedersen A, et al. Rodenticide-induced coagulopathy in a young child. A case of Munchausen syndrome by proxy. Am J Pediatr Hematol Oncol. 1993;15(1):126-130.

Pages: 1 2 3 4 | Single Page

Topics: brodifacoumCannabisCase PresentationCase ReportscoagulopathycoumarinMarijuanarat poisonrodenticidewarfarin

Related

  • Two Cases of Female Patients with Peritonitis

    April 23, 2025 - 0 Comment
  • Case Report: Murine Typhus Presents as Severe Pneumonia and Sepsis

    February 19, 2025 - 0 Comment
  • Case Report: Acute Kratom Withdrawal

    February 11, 2025 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

No Responses to “Tainted Synthetic Cannabis Leads to Coagulopathy Outbreak”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603